Albireo to Report First Quarter 2021 Financial Results on May 6
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will host a conference
call and live audio webcast at 10:00 a.m. ET on May 6,
2021, to provide a business update and review the company’s
financial results for the first quarter ended March 31, 2021.
To access the live conference call by phone, please dial
888-599-8686 (domestic) or 323-994-2082 (international) and provide
the access code 8407763. A live audio webcast will be accessible
from the Media & Investors page of Albireo’s
website, https://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3 trials
in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA
granted Priority Review and set a PDUFA goal date of July 20, 2021.
In Europe, the EMA validated MAA.Odevixibat is the only IBATi
granted accelerated assessment by the EMA. The Company has also
initiated a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
moving ahead with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. The Boston Business Journal named Albireo one
of the 2020 Best Places to Work in Massachusetts for the second
consecutive year. For more information on Albireo, please visit
Media Contact:Colleen Alabiso,
857-356-3905, firstname.lastname@example.orgLisa Rivero,
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578